Episodes of Closing the Gaps in NSCLC

Fulfilling the Unmet Needs of NSCLC Patients

Guest: Deepa Rangachari, MD With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving. That’s why it’s so important to test for RET mutations in patients

Fulfilling the Unmet Needs of NSCLC Patients

Guest: Deepa Rangachari, MD Communication is the key to guiding patients with non-small cell lung cancer through testing and treatment, but what exactly does that look like? Dr. Deepa Rangachari, an oncologist at the Beth Israel Deacones

On the Forefront of NSCLC Treatment: Targeting RET Mutations

Guest: Deepa Rangachari, MD Communication is the key to guiding patients with non-small cell lung cancer through testing and treatment, but what exactly does that look like? Dr. Deepa Rangachari, an oncologist at the Beth Israel Deacones

The Importance of Symptom Management for NSCLC Patients

Guest: Deepa Rangachari, MD With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving. That’s why it’s so important to test for RET mutations in patients

New Approaches to Treating Non-Small Cell Lung Cancer

Guest: Deepa Rangachari, MD Living with non-small cell lung cancer means living with a daily burden of symptoms like fatigue, decreased appetite, and shortness of breath. Dr. Deepa Rangachari, an oncologist at Harvard’s Beth Israel Deaco

New Approaches to Treating Non-Small Cell Lung Cancer

Host: Jennifer Caudle, DO Guest: Deepa Rangachari, MD Survival rates for patients with non-small cell lung cancer have notably improved thanks to the development of targeted therapies and immunotherapies. With these recent advancements

The Importance of Symptom Management for NSCLC Patients

Host: Jennifer Caudle, DO Guest: Deepa Rangachari, MD Survival rates for patients with non-small cell lung cancer have notably improved thanks to the development of targeted therapies and immunotherapies. With these recent advancements

What to Consider When Testing for Oncogenic Drivers in NSCLC

Guest: Deepa Rangachari, MD Living with non-small cell lung cancer means living with a daily burden of symptoms like fatigue, decreased appetite, and shortness of breath. Dr. Deepa Rangachari, an oncologist at Harvard’s Beth Israel Deaco

Mechanisms of Acquired Resistance to Targeted Therapies in NSCLC

Guest: Joshua M. Bauml, MD Now that there are more targeted therapies available for metastatic non-small cell lung cancer, what are the best practices for evaluating our patients? Dr. Joshua Bauml elaborates on the opportunities and chal

RET Fusions vs. RET Point Mutations: Understanding the Difference

Guest: Joshua M. Bauml, MD When a patient with non-small cell lung cancer harboring a molecular driver alteration develops resistance to their therapy, it’s important that we identify what the source of that resistance is, as Dr. Joshua

Targeting Oncogenic Drivers in NSCLC: Opportunities & Challenges

Guest: Joshua M. Bauml, MD Tune in to hear medical oncologist Dr. Joshua Bauml from the University of Pennsylvania explain the difference between RET fusions and RET point mutations and how they each affect our treatment approach.

Mechanisms of Acquired Resistance to Targeted Therapies in NSCLC

Host: Mario R. Nacinovich, Jr., MSc Guest: Lyudmila Bazhenova, MD Targeted therapies for oncogenic mutations in non-small cell lung cancer have shown a lot of potential when it comes to tailoring systemic treatment strategies to more s

How COVID-19 Has Impacted the Care Continuum for NSCLC Patients

Guest: Joshua M. Bauml, MD When a patient with non-small cell lung cancer harboring a molecular driver alteration develops resistance to their therapy, it’s important that we identify what the source of that resistance is, as Dr. Joshua

Exploring RET-Targeted Cancer Diagnosis & Treatment Strategies

Guest: Joshua M. Bauml, MD The COVID-19 pandemic has presented a unique and difficult problem for clinicians and patients alike. Here to share how he’s continuing treatment for his patients with non-small cell lung cancer in the era of C

RET Fusions vs. RET Point Mutations: Understanding the Difference

Guest: Joshua M. Bauml, MD When a patient presents with non-small cell lung cancer, one question that comes up is: Could this patient have a RET fusion? Here to explore how we can answer that question is Dr. Joshua Bauml, medical oncolog

Targeting Oncogenic Drivers in NSCLC: Opportunities & Challenges

Guest: Joshua M. Bauml, MD Tune in to hear medical oncologist Dr. Joshua Bauml from the University of Pennsylvania explain the difference between RET fusions and RET point mutations and how they each affect our treatment approach.

What to Consider When Testing for Oncogenic Drivers in NSCLC

Host: Mario R. Nacinovich, Jr., MSc Guest: Lyudmila Bazhenova, MD Targeted therapies for oncogenic mutations in non-small cell lung cancer have shown a lot of potential when it comes to tailoring systemic treatment strategies to more s

Exploring RET-Targeted Cancer Diagnosis & Treatment Strategies

Guest: Joshua M. Bauml, MD Now that there are more targeted therapies available for metastatic non-small cell lung cancer, what are the best practices for evaluating our patients? Dr. Joshua Bauml elaborates on the opportunities and chal

How COVID-19 Has Impacted the Care Continuum for NSCLC Patients

Guest: Joshua M. Bauml, MD When a patient presents with non-small cell lung cancer, one question that comes up is: Could this patient have a RET fusion? Here to explore how we can answer that question is Dr. Joshua Bauml, medical oncolog